Serum M2-pyruvate kinase: A promising non-invasive biomarker for colorectal cancer mass screening

Table 2 The area under the receiver operating characteristic curve and 95% confidence interval of serum pyruvate kinase isoenzyme M2 in U/mL and carcinoembryonic antigen in ng/mL in diagnosing colorectal lesions in colorectal cancer mass screening in Hangzhou, China, 2006-2008

Colorectal lesion	Test	AUC	SE	P-value	95% CI
CRC stage I and II	CEA	0.70	0.04	< 0.0001	0.62-0.79
	M2-PK	0.89	0.03	< 0.0001	0.84-0.94
CRC stage III	CEA	0.73	0.05	< 0.0001	0.63-0.83
	M2-PK	0.89	0.03	< 0.0001	0.84-0.94
Advanced adenoma	CEA	0.63	0.05	0.01	0.53-0.73
	M2-PK	0.81	0.04	< 0.0001	0.74-0.86
Adenoma	CEA	0.54	0.03	0.28	0.47-0.60
	M2-PK	0.69	0.03	< 0.0001	0.64-0.76
Nonadenomatous polyp	CEA	0.58	0.05	0.09	0.48-0.68
	M2-PK	0.69	0.04	< 0.0001	0.62-0.78
Inflammatory bowel disease	CEA	0.41	0.10	0.40	0.21-0.61
	M2-PK	0.42	0.10	0.40	0.21-0.63

AUC: Area under the receiver operating characteristic curve; CRC: Colorectal cancer; CI: Confidence interval; M2-PK: M2-pyruvate kinase; CEA: Carcinoembryonic antigen.